MCID: PTH002
MIFTS: 48

Pathological Gambling

Categories: Mental diseases

Aliases & Classifications for Pathological Gambling

MalaCards integrated aliases for Pathological Gambling:

Name: Pathological Gambling 12 15 17 33
Compulsive Gambling 12 43
Gambling, Pathological 72
Gambling 44

Classifications:



External Ids:

Disease Ontology 12 DOID:12399
ICD9CM 35 312.31
MeSH 44 D005715
NCIt 50 C94335
SNOMED-CT 68 18085000
ICD10 33 F63.0
UMLS 72 C0030662

Summaries for Pathological Gambling

MedlinePlus : 43 Many people enjoy gambling, whether it's betting on a horse or playing poker on the Internet. Most people who gamble don't have a problem, but some lose control of their gambling. Signs of problem gambling include Always thinking about gambling Lying about gambling Spending work or family time gambling Feeling bad after you gamble, but not quitting Gambling with money you need for other things If you have concerns about your gambling, ask for help. Your health care provider can work with you to find the treatment that's best for you. NIH: National Institutes of Health

MalaCards based summary : Pathological Gambling, also known as compulsive gambling, is related to impulse control disorder and avoidant personality disorder. An important gene associated with Pathological Gambling is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Beta-Adrenergic Signaling and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Methylphenidate and Ropinirole have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are behavior/neurological and cardiovascular system

Disease Ontology : 12 An impulse control disorder that involves the uncontrollable impulse to gamble, irrespective of the interference the behaviour has on the individual's life.

Related Diseases for Pathological Gambling

Diseases related to Pathological Gambling via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)
# Related Disease Score Top Affiliating Genes
1 impulse control disorder 31.3 DRD4 DRD3 DRD2
2 avoidant personality disorder 30.8 SLC6A4 MAOA
3 alexithymia 30.7 SLC6A4 DRD2
4 restless legs syndrome 30.5 SLC6A3 DRD3 DRD2
5 drug dependence 30.4 SLC6A4 DRD3 DRD2
6 heroin dependence 30.3 DRD4 DRD2
7 stuttering 30.3 SLC6A3 DRD2
8 dysthymic disorder 30.3 SLC6A4 MAOA
9 eating disorder 30.2 SLC6A4 SLC6A3 DRD2
10 movement disease 30.2 SLC6A3 DRD3 DRD2
11 borderline personality disorder 30.1 SLC6A4 MAOA
12 kleptomania 30.1 SLC6A4 MAOA
13 separation anxiety disorder 30.1 SLC6A3 DRD4
14 delusional disorder 30.0 DRD4 DRD3 DRD2
15 bipolar i disorder 30.0 SLC6A4 DRD1
16 opiate dependence 30.0 SLC6A4 DRD3 DRD2
17 schizoaffective disorder 30.0 SLC6A4 DRD3 DRD2
18 agoraphobia 29.9 SLC6A4 MAOA
19 mental depression 29.9 SLC6A4 MAOA
20 cocaine dependence 29.9 SLC6A4 SLC6A3 DRD3 DRD2
21 bipolar disorder 29.9 SLC6A4 SLC6A3 DRD3 DRD2
22 generalized anxiety disorder 29.8 SLC6A4 MAOA DRD2
23 phobic disorder 29.7 SLC6A4 MAOA
24 cocaine abuse 29.6 SLC6A4 SLC6A3 DRD2
25 tobacco addiction 29.6 SLC6A4 SLC6A3 MAOA DRD2
26 personality disorder 29.5 SLC6A4 SLC6A3 MAOA DRD4 DRD2
27 social phobia 29.4 SLC6A4 MAOA DRD2
28 endogenous depression 29.4 SLC6A4 MAOA
29 dependent personality disorder 29.3 MAOB MAOA DRD4
30 gilles de la tourette syndrome 29.1 SLC6A3 DRD5 DRD4 DRD2
31 post-traumatic stress disorder 29.1 SLC6A4 MAOB MAOA DRD2
32 dystonia 29.0 SLC6A3 DRD5 DRD2
33 antisocial personality disorder 29.0 SLC6A4 SLC6A3 MAOB MAOA DRD2
34 mood disorder 28.8 SLC6A4 MAOB MAOA DRD4 DRD3 DRD2
35 tic disorder 28.7 SLC6A3 DRD5 DRD4 DRD2
36 obsessive-compulsive disorder 28.3 SLC6A4 SLC6A3 MAOA DRD4 DRD3 DRD2
37 major depressive disorder 28.2 SLC6A4 SLC6A3 MAOA DRD4 DRD3 DRD2
38 oppositional defiant disorder 28.2 SLC6A4 SLC6A3 MAOA DRD4 DRD2
39 disease of mental health 28.2 SLC6A4 SLC6A3 MAOA DRD4 DRD3 DRD2
40 parkinson disease, late-onset 28.0 SLC6A4 SLC6A3 MAOB MAOA DRD3 DRD2
41 migraine with or without aura 1 28.0 SLC6A4 MAOA DRD5 DRD3 DRD2
42 substance abuse 27.9 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD3
43 alcohol dependence 27.7 SLC6A4 SLC6A3 MAOB MAOA DRD4 DRD3
44 psychotic disorder 27.6 SLC6A4 SLC6A3 MAOB DRD4 DRD3 DRD2
45 substance dependence 27.6 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD3
46 conduct disorder 27.3 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD2
47 attention deficit-hyperactivity disorder 26.1 SLC6A4 SLC6A3 MAOB MAOA DRD5 DRD4
48 schizophrenia 25.7 SLC6A4 SLC6A3 MAOB MAOA DRD5 DRD4
49 gambling, pathologic 11.9
50 congenital chloride diarrhea 11.8

Graphical network of the top 20 diseases related to Pathological Gambling:



Diseases related to Pathological Gambling

Symptoms & Phenotypes for Pathological Gambling

MGI Mouse Phenotypes related to Pathological Gambling:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 DRD1 DRD2 DRD3 DRD4 DRD5 MAOA
2 cardiovascular system MP:0005385 9.63 DRD1 DRD2 DRD3 DRD5 MAOA SLC6A4
3 homeostasis/metabolism MP:0005376 9.56 DRD1 DRD2 DRD3 DRD4 MAOA MAOB
4 nervous system MP:0003631 9.28 DRD1 DRD2 DRD3 DRD4 DRD5 MAOA

Drugs & Therapeutics for Pathological Gambling

Drugs for Pathological Gambling (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
2
Ropinirole Approved, Investigational Phase 4 91374-21-9, 91374-20-8 5095 497540
3
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
4
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
5
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
6
Nicotine Approved Phase 4 54-11-5 942 89594
7
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
8 Central Nervous System Stimulants Phase 4
9 Cholinergic Agents Phase 4
10 Nicotinic Agonists Phase 4
11 Neurotransmitter Uptake Inhibitors Phase 4
12 Autonomic Agents Phase 4
13 Dopamine agonists Phase 4
14 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
15 Antidepressive Agents, Second-Generation Phase 4
16 Dopamine Uptake Inhibitors Phase 4
17 Cytochrome P-450 Enzyme Inhibitors Phase 4
18 Sympathomimetics Phase 4
19 Cardiotonic Agents Phase 4
20 Protective Agents Phase 4
21
Ketamine Approved, Vet_approved Phase 2, Phase 3 6740-88-1 3821
22
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
23
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
24
Risperidone Approved, Investigational Phase 3 106266-06-2 5073
25
Ethanol Approved Phase 3 64-17-5 702
26 Excitatory Amino Acid Antagonists Phase 2, Phase 3
27 Excitatory Amino Acids Phase 2, Phase 3
28 Analgesics Phase 2, Phase 3
29 Anesthetics, Intravenous Phase 2, Phase 3
30 Anesthetics, General Phase 2, Phase 3
31 Anesthetics, Dissociative Phase 2, Phase 3
32 Antiemetics Phase 3
33 Gastrointestinal Agents Phase 3
34 Dopamine Agents Phase 3
35 Tranquilizing Agents Phase 3
36 Central Nervous System Depressants Phase 3
37 Dopamine Antagonists Phase 3
38 Antipsychotic Agents Phase 3
39 Psychotropic Drugs Phase 3
40 Serotonin Agents Phase 3
41 Serotonin Antagonists Phase 3
42
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
43
Coal tar Approved Phase 2 8007-45-2
44
Memantine Approved, Investigational Phase 2 19982-08-2 4054
45
Dextroamphetamine Approved, Illicit Phase 2 51-64-9 5826
46
Fluphenazine Approved Phase 2 69-23-8 3372
47
Amphetamine Approved, Illicit, Investigational Phase 2 300-62-9 5826 3007
48
Haloperidol Approved Phase 2 52-86-8 3559
49
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
50
Milk thistle Approved, Experimental, Investigational Phase 2 65666-07-1

Interventional clinical trials:

(show top 50) (show all 172)
# Name Status NCT ID Phase Drugs
1 Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
2 Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study Unknown status NCT01216904 Phase 4 nicotine patch;placebo
3 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention - a Placebo Controlled Trial Completed NCT01528007 Phase 4 Naltrexone pharmacotherapy;Placebo
4 Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
5 Open Label, Flexible Dose 12-Week Clinical Trial of the Safety and Efficacy of Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4 acamprosate
6 Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles. Completed NCT01733199 Phase 4
7 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
8 Neuropsychological and Psychopathological Prognosis Factors of Smoking Cessation Completed NCT01554436 Phase 4
9 Neurocognitive and Metabolic Effects of Mild Hypothyroidism Completed NCT00565864 Phase 4 L-thyroxine (L-T4)
10 An Open Prospective Trial of IV Ketamine in Suicidal Adolescents Unknown status NCT02048423 Phase 2, Phase 3 Ketamine
11 Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling Completed NCT00438776 Phase 3 olanzapine;sugar pill
12 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling Completed NCT00132119 Phase 2, Phase 3 nalmefene HCl
13 Minimal and Brief Treatments for Pathological Gamblers: Developing Effective Treatment Systems Completed NCT00203645 Phase 3
14 Naltrexone Treatment in Pathologic Gambling Disorder Completed NCT00053677 Phase 3 Naltrexone;Placebo
15 The Effect of Transcranial Direct Current Stimulation on Decision Making and Cognitive Flexibility in Gambling Disorder Completed NCT03477799 Phase 3
16 The Efficacy of Functional Magnetic Resonance Imaging (fMRI) Guided Low Frequency Repetitive Magnetic Transcranial Stimulation (rTMS) Therapy on Symptoms of Generalized Anxiety Disorder (GAD) Completed NCT00662584 Phase 3
17 Modulating Inhibitory Control Networks in Gambling Disorder With Theta Burst Stimulation Recruiting NCT03669315 Phase 3
18 Evaluation of Predictability of the Initial Response to a Low Dose of Risperidone on the Middle Term Efficiency in Anxious Subjects Recruiting NCT03227562 Phase 3 RisperiDONE 0.5 MG
19 EEG/Event-related Brain Potential Risk Markers as Predictors and Outcomes of SUD Treatment in Adolescents Active, not recruiting NCT02016378 Phase 3
20 Topiramate in the Treatment of Pathological Gambling: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study Terminated NCT00245583 Phase 3 Topiramate;Placebo
21 RTC of Web Versus In-Person SUD and Comorbidity Treatment Unknown status NCT01529047 Phase 2
22 Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study Unknown status NCT02934919 Phase 2 Nalmefene
23 Evaluating the Benefits of the Community Reinforcement and Family Training(CRAFT) Approach to Concerned Significant Others(CSO) of Individuals Engaged in Problem Gambling (IPGs) Unknown status NCT01340274 Phase 2
24 A Phase II Open-Label Multi-Center Trial of Memantine (Namenda(TM)) Treatment of Pathological Gambling Completed NCT00585169 Phase 2 Memantine Hydrochloride
25 Ecopipam Treatment of Pathological Gambling Completed NCT01215357 Phase 2 Ecopipam
26 Tolcapone Treatment of Pathological Gambling: An Open-Label Study Completed NCT00927563 Phase 2 Tolcapone
27 Indicated Prevention With At-Risk Gamblers Completed NCT00078273 Phase 2
28 Double-blind Placebo Controlled Topiramate Trial for Pathological Gamblers Completed NCT01843699 Phase 2 Topiramate flexible dosage;Placebo matching tablets
29 Cognitive Behavioral Therapy for Pathological Gambling Completed NCT00337753 Phase 2
30 Comparative Effects of a D2 and Mixed D1-D2 Dopamine Antagonist on Gambling and Amphetamine Reinforcement in Pathological Gamblers and Healthy Controls Completed NCT02203786 Phase 2 Haloperidol;Fluphenazine;Dexedrine;Placebo
31 Double Blind Controlled Trial of Topiramate for Compulsive Buying Completed NCT02138058 Phase 2 Topiramate
32 Double-Blind Placebo-Controlled Investigation of Naltrexone for Pathological Gambling Completed NCT01057862 Phase 2 Naltrexone
33 N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers Completed NCT00967005 Phase 2 N Acetyl Cysteine
34 Pilot Study: Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray Completed NCT03223896 Phase 2 Naloxone hydrochloride 20mg/ml
35 Use of Massage Therapy to Reduce Anxiety and Improve Sleep in Patients Participating in an Inpatient Withdrawal Management (Detox) Program: A Randomized Controlled Pilot Study Completed NCT00992979 Phase 2
36 Silymarin Treatment of Pathological Gambling: A Double-Blind, Placebo-Controlled Study Recruiting NCT02337634 Phase 2 Placebo;Milk Thistle
37 Double-blind, Placebo-controlled Randomised Study on the Efficacy of Naloxone Nasal Spray for the Treatment of Gambling Disorder Enrolling by invitation NCT03430180 Phase 2 Naloxone hydrochloride;Placebo
38 Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease Not yet recruiting NCT03947216 Phase 2 Active drug: pimavanserin 17mg (2 strength tablets);Placebo: 2 tablets containing same excipients except active compound
39 A Pilot Study of Sertraline Plus Relapse Prevention Therapy (RP) for the Treatment of Pathological Gambling With Comorbid Abuse or Dependence Terminated NCT00249431 Phase 2 Sertraline
40 Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers Terminated NCT01764685 Phase 2 Topiramate;Placebo
41 The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia Terminated NCT00547118 Phase 2 Rimonabant;Placebo
42 Clinical Assessment of Topiramate on Gambling-Related Behaviours in Problem Gamblers: Effects of Gender and Negative Emotionality Withdrawn NCT00370188 Phase 2 Topiramate
43 Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling Unknown status NCT01154712 Phase 1
44 Enhanced Cognitive Behavior Therapy for the Treatment of Pathological Gambling Completed NCT00118391 Phase 1
45 Cognitive-Motivational Behavior Therapy for Gamblers Completed NCT00069420 Phase 1
46 An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling Completed NCT00273702 Phase 1 N-Acetyl Cysteine
47 Acute Effects of Smoked Marijuana on Decision Making, as Assessed by a Modified Gambling Task, in Experienced Marijuana Users Completed NCT00373399 Phase 1 Inactive Marijuana (0% THC);Low THC marijuana (1.8 %THC);High THC marijuana (3.9% THC)
48 Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE) Completed NCT01437293 Phase 1 L-dopa / carbidopa / entacapone (LCE)
49 N-Acetylcysteine in the Treatment of Deliberate Self-Harm in Adolescents: An Open Label Pilot Study Completed NCT01111734 Phase 1 fMRI
50 The Effect of Regular Naltrexone Dosing on Disordered Gamblers: An Examination of Neural Activation, Gambling Urges, and Gambling Behaviour Recruiting NCT02537197 Phase 1 Naltrexone

Search NIH Clinical Center for Pathological Gambling

Cochrane evidence based reviews: gambling

Genetic Tests for Pathological Gambling

Anatomical Context for Pathological Gambling

MalaCards organs/tissues related to Pathological Gambling:

41
Brain, Cortex, Testes, Prefrontal Cortex, Subthalamic Nucleus, Eye, Liver

Publications for Pathological Gambling

Articles related to Pathological Gambling:

(show top 50) (show all 1868)
# Title Authors PMID Year
1
Addiction beyond pharmacological effects: The role of environment complexity and bounded rationality. 38 17
31125913 2019
2
No limit: AI poker bot is first to beat professionals at multiplayer game. 17
31312056 2019
3
Problem gambling and associated mental health concerns in elite athletes: a narrative review. 17
31151953 2019
4
Striatal presynaptic dopaminergic dysfunction in gambling disorder: A 123 I-FP-CIT SPECT study. 38
30226290 2019
5
Religiosity and Chance Beliefs in Persons with DSM-IV Pathological Gambling Enrolled in a Longitudinal Follow-Up Study. 38
31115747 2019
6
An Exploratory Study of Relationships Among Five-Factor Personality Measures and Forms of Gambling in Adults With and Without Probable Pathological Gambling. 38
30382456 2019
7
Impulse control disorders in Parkinson's disease versus in healthy controls: A different predictive model. 38
31423741 2019
8
Overlapping dimensional phenotypes of impulsivity and compulsivity explain co-occurrence of addictive and related behaviors. 38
30458896 2019
9
Effects of nicotine exposure and anxiety on motivation for reward and gambling-like cues under reward uncertainty. 38
30869950 2019
10
Let's Call it Quits: Break-Even Effects in the Decision to Stop Taking Risks. 38
30650213 2019
11
Prevalence of Gambling Disorder Among Prisoners: A Systematic Review. 38
31315486 2019
12
Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. 38
30848825 2019
13
Connecting with a Slot Machine: Social Exclusion and Anthropomorphization Increase Gambling. 38
29959690 2019
14
A Systematic Review of Land-Based Self-Exclusion Programs: Demographics, Gambling Behavior, Gambling Problems, Mental Symptoms, and Mental Health. 38
29721719 2019
15
Youth Gambling in Hong Kong: Prevalence, Psychosocial Correlates, and Prevention. 38
31122548 2019
16
Compulsive sexual behavior disorder in obsessive-compulsive disorder: Prevalence and associated comorbidity. 38
31079471 2019
17
Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. 38
31136681 2019
18
Creativity related to dopaminergic treatment: A multicenter study. 38
30824283 2019
19
Cannabis use, problem-gambling severity, and psychiatric disorders: Data from the national epidemiological survey on alcohol and related conditions. 38
31246071 2019
20
Pathological Gambling in a Patient on a Dopamine Agonist. 38
31167528 2019
21
Clinical Improvements in Comorbid Gambling/Cocaine Use Disorder (GD/CUD) Patients Undergoing Repetitive Transcranial Magnetic Stimulation (rTMS). 38
31151221 2019
22
The relationship between memory associations, gambling involvement, and problem gambling. 38
30579883 2019
23
Locating gambling problems across a continuum of severity: Rasch analysis of the Quinte Longitudinal Study (QLS). 38
30579115 2019
24
Two Cases of De Novo Pathological Gambling Associated With Aripiprazole. 38
31082834 2019
25
A case of pathological gambling. 38
31142915 2019
26
Impulse control disorders in Parkinson disease: A cross-sectional study in Morocco. 38
30935674 2019
27
Deficits in emotion regulation strategies among problematic and pathological gamblers in a sample of vocational school students. 38
30663330 2019
28
Effects of Gambling Diagnostic Criteria Changes from DSM-IV to DSM-5 on Mental Disorder Comorbidity Across Younger, Middle-Aged, and Older Adults in a Nationally Representative Sample. 38
30167940 2019
29
Addictive Video Game Use: An Emerging Pediatric Problem? 38
30946788 2019
30
Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control. 38
30753324 2019
31
The Multidimensional Structure of Problem Gambling: An Evaluation of Four Gambling Categorization Instruments from an International Online Survey of Gamblers. 38
30793249 2019
32
Nancy M. Petry (1968-2018). 38
30762395 2019
33
Cognitive bias modification in problem and pathological gambling using a web-based approach-avoidance task: A pilot trial. 38
30583260 2019
34
[Addictions]. 38
30629359 2019
35
A self-guided Internet-based intervention for individuals with gambling problems: study protocol for a randomized controlled trial. 38
30674348 2019
36
Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review. 38
31057473 2019
37
THE PROBLEM OF CO-DEPENDENCE AMONG HIV-INFECTED DRUG-ADDICTED FAMILY MEMBERS. 38
30829596 2019
38
Impulsive-Compulsive Behaviours in Belgian-Flemish Parkinson's Disease Patients: A Questionnaire-Based Study. 38
31011412 2019
39
Wait and you shall see: sexual delay discounting in hypersexual Parkinson's disease. 38
30590514 2019
40
Factors Precipitating Calls to a Help Hotline: A Comparison of Whites, Blacks, and Hispanics. 38
30604034 2019
41
Gender differences in mental health and substance use disorders and related healthcare services utilization. 38
30536669 2019
42
Drugs-Induced Pathological Gambling: An Analysis of Italian Spontaneous Reporting System. 38
30671764 2019
43
Posttraumatic Stress Disorder Is a Risk Factor for Multiple Addictions in Police Officers Hospitalized for Alcohol. 38
31117072 2019
44
Early pathological gambling in co-occurrence with semantic variant primary progressive aphasia: a case report. 38
31114177 2019
45
Behavioral addictions in bipolar disorders: A systematic review. 38
30420190 2019
46
Motor Preparation for Action Inhibition: A Review of Single Pulse TMS Studies Using the Go/NoGo Paradigm. 38
30846954 2019
47
Gambling behavior in Parkinson's Disease: Impulsivity, reward mechanism and cortical brain oscillations. 38
29580652 2018
48
Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease. 38
30444952 2018
49
In Search of Executive Impairment in Pathological Gambling: A Neuropsychological Study on Non-treatment Seeking Gamblers. 38
29455442 2018
50
Prevalence of internet gaming disorder in adolescents: A meta-analysis across three decades. 38
30004118 2018

Variations for Pathological Gambling

Expression for Pathological Gambling

Search GEO for disease gene expression data for Pathological Gambling.

Pathways for Pathological Gambling

Pathways related to Pathological Gambling according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 DRD5 DRD4 DRD3 DRD2 DRD1
2 12.12 DRD5 DRD4 DRD3 DRD2 DRD1
3
Show member pathways
12.1 SLC6A3 MAOB MAOA DRD5 DRD4 DRD3
4 12.06 DRD5 DRD2 DRD1
6
Show member pathways
11.95 DRD5 DRD4 DRD2 DRD1
7 11.75 SLC6A4 MAOB MAOA
8
Show member pathways
11.72 SLC6A3 MAOB MAOA DRD2 DRD1
9
Show member pathways
11.68 DRD4 DRD3 DRD2
10
Show member pathways
11.6 DRD5 DRD4 DRD3 DRD2 DRD1
11
Show member pathways
11.36 MAOB MAOA
12
Show member pathways
11.31 MAOB MAOA
13
Show member pathways
11.29 SLC6A4 SLC6A3 MAOA
14 11.24 DRD2 DRD1
15
Show member pathways
11.12 MAOB MAOA
16 11.08 SLC6A3 MAOB
17 11.01 SLC6A4 MAOA
18
Show member pathways
11 SLC6A4 SLC6A3 MAOA
19
Show member pathways
10.72 MAOB MAOA
20 10.68 MAOB MAOA
21
Show member pathways
10.64 MAOB MAOA
22 10.6 DRD5 DRD3 DRD2 DRD1

GO Terms for Pathological Gambling

Cellular components related to Pathological Gambling according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 SLC6A4 SLC6A3 DRD5 DRD4 DRD3 DRD2
2 glutamatergic synapse GO:0098978 9.76 DRD4 DRD3 DRD2 DRD1
3 GABA-ergic synapse GO:0098982 9.61 DRD3 DRD2 DRD1
4 ciliary membrane GO:0060170 9.54 DRD5 DRD2 DRD1
5 non-motile cilium GO:0097730 9.5 DRD5 DRD2 DRD1
6 dopaminergic synapse GO:0098691 9.33 SLC6A3 DRD3 DRD2
7 integral component of presynaptic membrane GO:0099056 9.26 SLC6A4 SLC6A3 DRD2 DRD1
8 integral component of postsynaptic membrane GO:0099055 8.92 SLC6A4 SLC6A3 DRD2 DRD1
9 membrane GO:0016020 10.13 SLC6A4 SLC6A3 MAOB MAOA DRD5 DRD4
10 integral component of membrane GO:0016021 10.06 SLC6A4 SLC6A3 MAOB MAOA DRD5 DRD4

Biological processes related to Pathological Gambling according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.93 SLC6A4 SLC6A3 MAOB DRD3 DRD2 DRD1
2 response to ethanol GO:0045471 9.88 SLC6A3 MAOB DRD3 DRD2
3 locomotory behavior GO:0007626 9.86 SLC6A3 DRD3 DRD2 DRD1
4 cellular calcium ion homeostasis GO:0006874 9.85 DRD5 DRD4 DRD3
5 response to toxic substance GO:0009636 9.85 SLC6A4 MAOB DRD2
6 social behavior GO:0035176 9.81 SLC6A4 DRD4 DRD3
7 visual learning GO:0008542 9.8 DRD3 DRD2 DRD1
8 associative learning GO:0008306 9.77 DRD5 DRD2 DRD1
9 negative regulation of blood pressure GO:0045776 9.77 DRD5 DRD3 DRD2
10 arachidonic acid secretion GO:0050482 9.76 DRD4 DRD3 DRD2
11 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.74 DRD3 DRD2
12 negative regulation of protein secretion GO:0050709 9.74 DRD4 DRD3 DRD2
13 negative regulation of protein kinase B signaling GO:0051898 9.73 DRD3 DRD2
14 circadian regulation of gene expression GO:0032922 9.73 DRD3 DRD2
15 regulation of synaptic vesicle exocytosis GO:2000300 9.73 DRD2 DRD1
16 neurotransmitter transport GO:0006836 9.73 SLC6A4 SLC6A3
17 response to nicotine GO:0035094 9.73 SLC6A3 DRD2
18 positive regulation of multicellular organism growth GO:0040018 9.73 SLC6A3 DRD2
19 positive regulation of cytokinesis GO:0032467 9.72 DRD3 DRD2
20 feeding behavior GO:0007631 9.72 DRD2 DRD1
21 activation of adenylate cyclase activity GO:0007190 9.72 DRD5 DRD1
22 adult walking behavior GO:0007628 9.72 DRD2 DRD1
23 response to morphine GO:0043278 9.72 DRD3 DRD2
24 regulation of dopamine metabolic process GO:0042053 9.72 SLC6A3 DRD4 DRD1
25 behavioral fear response GO:0001662 9.71 DRD4 DRD1
26 temperature homeostasis GO:0001659 9.71 DRD2 DRD1
27 transmission of nerve impulse GO:0019226 9.71 DRD5 DRD1
28 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.71 DRD3 DRD2
29 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.71 DRD4 DRD3 DRD2
30 behavioral response to cocaine GO:0048148 9.71 DRD4 DRD3 DRD2 DRD1
31 response to iron ion GO:0010039 9.7 SLC6A3 DRD2
32 long-term synaptic depression GO:0060292 9.7 DRD5 DRD1
33 striatum development GO:0021756 9.7 DRD2 DRD1
34 positive regulation of renal sodium excretion GO:0035815 9.7 DRD3 DRD2
35 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.7 DRD5 DRD3 DRD1
36 neurotransmitter biosynthetic process GO:0042136 9.69 SLC6A4 SLC6A3
37 grooming behavior GO:0007625 9.69 DRD2 DRD1
38 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.69 DRD4 DRD3
39 dopamine catabolic process GO:0042420 9.69 SLC6A3 MAOB MAOA
40 G protein-coupled receptor internalization GO:0002031 9.68 DRD3 DRD2
41 peristalsis GO:0030432 9.68 DRD2 DRD1
42 neurotransmitter catabolic process GO:0042135 9.68 MAOB MAOA
43 negative regulation of voltage-gated calcium channel activity GO:1901386 9.67 DRD4 DRD2
44 monoamine transport GO:0015844 9.67 SLC6A4 SLC6A3
45 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.67 DRD5 DRD2 DRD1
46 synaptic transmission, dopaminergic GO:0001963 9.67 DRD5 DRD3 DRD2 DRD1
47 behavioral response to ethanol GO:0048149 9.66 DRD4 DRD2
48 adenohypophysis development GO:0021984 9.66 SLC6A3 DRD2
49 mating behavior GO:0007617 9.65 DRD5 DRD1
50 cellular response to catecholamine stimulus GO:0071870 9.65 DRD5 DRD1

Molecular functions related to Pathological Gambling according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.83 DRD5 DRD4 DRD3 DRD2 DRD1
2 drug binding GO:0008144 9.56 SLC6A3 DRD4 DRD3 DRD2
3 G-protein alpha-subunit binding GO:0001965 9.49 DRD5 DRD1
4 adrenergic receptor activity GO:0004935 9.48 DRD3 DRD2
5 neurotransmitter:sodium symporter activity GO:0005328 9.46 SLC6A4 SLC6A3
6 monoamine transmembrane transporter activity GO:0008504 9.4 SLC6A4 SLC6A3
7 primary amine oxidase activity GO:0008131 9.37 MAOB MAOA
8 dopamine neurotransmitter receptor activity GO:0004952 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
9 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.33 DRD4 DRD3 DRD2
10 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.32 DRD5 DRD1
11 dopamine binding GO:0035240 9.1 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1

Sources for Pathological Gambling

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....